Lumateperone

Lumateperone

SCHEMBL29558708

CN1CCN2c3c(cccc31)[C@@H]1CN(CCCC(=O)c3ccc(F)cc3)CC[C@@H]12.Cc1ccc(S(=O)(=O)O)cc1.Cc1ccc(S(=O)(=O)O)cc1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

DRD2HTR2ASLC6A4

The experimentally established mechanism targets of Lumateperone. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 10)

geneUniProtsupporting neighboursconfidence
HTR2A known ✓ P28223 18/20 1.00
SLC6A4 known ✓ P31645 4/20 1.00
DRD2 known ✓ P14416 1/20 0.83
HTR2C P28335 15/20 1.00
HTR1A P08908 1/20 1.00
DRD1 P21728 1/20 1.00
DRD4 P21917 1/20 1.00
ADRA1A P35348 1/20 1.00
ADRA1B P35368 1/20 1.00
CCR3 P51677 1/20 0.64

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Lumateperone SCHEMBL29355976 1.00 HTR2A (1.00) HTR2AHTR2CSLC6A4HTR1ADRD1
Lumateperone SCHEMBL1769664 1.00 HTR2A (1.00) HTR2AHTR2CSLC6A4HTR1ADRD1
Lumateperone SCHEMBL22635597 0.96 HTR2A (0.91) HTR2AHTR2CSLC6A4HTR1ADRD1
Lumateperone SCHEMBL31465557 0.96 HTR2A (0.91) HTR2AHTR2CSLC6A4HTR1ADRD1
Lumateperone SCHEMBL21996433 0.94 HTR2A (0.88) HTR2AHTR2CSLC6A4HTR1ADRD1
Lumateperone SCHEMBL31032326 0.94 HTR2A (0.88) HTR2AHTR2CSLC6A4HTR1ADRD1
Lumateperone SCHEMBL16005572 0.91 HTR2A (0.90) HTR2AHTR2CSLC6A4HTR1ADRD1
Lumateperone SCHEMBL22067597 0.91 HTR2A (1.00) HTR2AHTR2CSLC6A4HTR1ADRD1
Lumateperone SCHEMBL21524899 0.91 HTR2A (1.00) HTR2AHTR2CSLC6A4HTR1ADRD1
Lumateperone SCHEMBL17681371 0.91 HTR2A (1.00) HTR2AHTR2CSLC6A4HTR1ADRD1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230382914-A1 SOLID STATE FORMS OF LUMATEPERONE DITOSYLATE SALT TEVA PHARMACEUTICALS INTERNATIONAL GMBH (CH) 2023-11-30 US disclosed
US-11760757-B2 Solid state forms of lumateperone ditosylate salt TEVA PHARMACEUTICALS INTERNATIONAL GMBH (CH) 2023-09-19 US disclosed
EP-4001281-A1 SOLID STATE FORMS OF LUMATEPERONE DITOSYLATE SALT AND PREPARATION THEREOF Teva Pharmaceuticals International GmbH (CH) 2022-05-25 EP disclosed
US-11332469-B2 Solid state forms of lumateperone ditosylate salt TEVA PHARMACEUTICALS INTERNATIONAL GMBH (CH) 2022-05-17 US disclosed
US-20220127268-A1 SOLID STATE FORMS OF LUMATEPERONE DITOSYLATE SALT ASSIA CHEMICAL INDUSTRIES LTD. (IL) 2022-04-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11760757-B2 Solid state forms of lumateperone ditosylate salt LSS, DHPS, LPXN HTR2A 1890/4885SLC6A4 215/4885DRD2 1115/4885
US-20220127268-A1 SOLID STATE FORMS OF LUMATEPERONE DITOSYLATE SALT LSS, DHPS, LPXN HTR2A 1890/4885SLC6A4 215/4885DRD2 1115/4885
US-11332469-B2 Solid state forms of lumateperone ditosylate salt LSS, DHPS, LPXN HTR2A 1890/4885SLC6A4 215/4885DRD2 1115/4885
US-20230382914-A1 SOLID STATE FORMS OF LUMATEPERONE DITOSYLATE SALT LSS, DHPS, LPXN HTR2A 1890/4885SLC6A4 215/4885DRD2 1115/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.